A multi-metabolite signature robustly predicts long-term mortality in the PREDIMED trial and several US cohorts
{{output}}
Metabolome-based biomarkers contribute to identify mechanisms of disease and to a better understanding of overall mortality. In a long-term follow-up subsample (n = 1878) of the PREDIMED trial, among 337 candidate baseline plasma metabolites repeatedly assesse... ...
